emerging glp-1 gip obesity treatments 2025 Dual and Triple Gut Peptide Agonists on the Horizon for the Treatment of Type 2 Diabetes and Obesity. An Overview of Preclinical and Clinical Data | Current Reports GLP-1 Pipeline Update: May 2025

Risk factors for type 2 diabetes mellitus: an exposure-wide umbrella review of meta-analyses

These measurement changes often exceed what the raw weight loss would predict, because the shift in body composition means the body is not just smaller but shaped differently

In short, the standard prescribe and refer back in 3 months approach leaves a support vacuum

doi: 10.1016/b978-0-12-571131-9.50017-7 13 BellGISanchez-PescadorRLaybournPJNajarianRC

At REAL Weight Loss & Wellness , she leads physician-supervised, non-surgical programs developed around each patients health history, challenges, and goals

10.1093/jac/dkz515 5 BartholomeuD